Efficacy and safety results from neopembrov study, a randomized phase II trial of neoadjuvant chemotherapy (CT) with or without pembrolizumab (P) followed by interval debulking surgery and standard systemic therapy ± P for advanced high-grade serous carcinoma (HGSC): A GINECO study.

Isabelle Ray-Coquard,Aude-Marie Savoye,Marie-Ange Mouret-Reynier,Sylvie Chabaud,Olfa Derbel,Elsa Kalbacher,Marianne Leheurteur,Alejandra Martinez,Corina Cornila,Mathilde Martinez,Leila Bengrine,Frank Priou,Nicolas Cloarec,Laurence Venat-Bouvet,Frédéric Selle,Dominique Berton,Olivier Collard,Florence Joly,Olivier Tredan

Efficacy and safety results from neopembrov study, a randomized phase II trial of neoadjuvant chemotherapy (CT) with or without pembrolizumab (P) followed by interval debulking surgery and standard systemic therapy ± P for advanced high-grade serous carcinoma (HGSC): A GINECO study.

2021

Isabelle Ray-Coquard
Aude-Marie Savoye
Marie-Ange Mouret-Reynier
Sylvie Chabaud
Olfa Derbel
Elsa Kalbacher
Marianne Leheurteur
Alejandra Martinez
Corina Cornila
Mathilde Martinez
Leila Bengrine
Frank Priou
Nicolas Cloarec
Laurence Venat-Bouvet
Frédéric Selle
Dominique Berton
Olivier Collard
Florence Joly
Olivier Tredan

5500Background: To investigate whether adding Pembrolizumab (P) to neoadjuvant carboplatin-paclitaxel chemotherapy (CP) may increase the optimal debulking rate, assessed by Complete Resection Rate ...

Keywords:

Systemic therapy
Medicine
High-grade serous carcinoma
Pembrolizumab
Chemotherapy
Debulking
Optimal Debulking
Surgery
complete resection

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations